Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.
Trial locations(7 sites)
United States
The University of Kansas Cancer Center, Westwood, Kansas Dana-Farber Cancer Institute, Boston, Massachusetts University of Nebraska Medical Center, Omaha, Nebraska Memorial Sloan Kettering Cancer Center, New York, New York University Hospitals Cleveland Medical Center, Case Comprehensive Cancer Center, Cleveland, Ohio Cleveland Clinic Taussig Cancer institute, Case Comprehensive Cancer Center, Cleveland, Ohio The James Cancer Hospital and Solove Research Institute, Columbus, Ohio